prana’s founding scientist to present at banc of

Prana’s Founding Scientist to Present at Banc of America Specialty Pharmaceuticals Conference: New Products, New Paradigms
Melbourne, Australia - July 27, 2004: Prana Biotechnology Limited (NASDAQ: PRAN,
ASX: PBT) today announced that its founding scientist Dr. Ashley Bush, of Harvard Medical
School, will present at the Banc of America Specialty Pharmaceuticals Conference: New
Products, New Paradigms, July 29-30, 2004 in Southampton, New York. Dr. Bush’s
presentation will be given Friday, July 30th at 11:00 am ET.
Founding scientists Drs. Rudolph Tanzi and Ashley Bush’s theories concerning the
interaction between metals and the protein beta-amyloid in the brain are the basis of Prana’s
treatments for Alzheimer's and other neurodegenerative diseases.
About Prana Biotechnology Limited
Prana Biotechnology was established to commercialize research into Alzheimer's disease
and other major age-related degenerative disorders. The company was incorporated in 1997
and listed on the Australian Stock Exchange in March 2000. Researchers at prominent
international institutions including the University of Melbourne and Massachusetts General
Hospital at Harvard Medical School discovered Prana’s technology.
This press release contains “forward looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995 regarding the Company’s business strategy and future plans of
operation. Forward-looking statements involve known and unknown risks and uncertainties; both
general and specific to the matters discussed in this press release. These and other important factors,
including those mentioned in various Securities and Exchange Commission filings made by the
Company, may cause the Company’s actual results and performance to differ materially from the
future results and performance expressed in or implied by such forward-looking statements. The
forward-looking statements contained in this press release speak only as of the date hereof and the
Company expressly disclaims any obligation to provide public updates, revisions or amendments to
any forward-looking statements made herein to reflect changes in the Company’s expectations or
future events.
For further information, please visit our web site at www.pranabio.com.
Contacts:
Company Media Investor
Geoffrey Kempler
Prana Biotechnology Ltd.
Ivette Almeida
The Anne McBride Company
Rachel Levine
The Anne McBride Company
61-3-9349-4906 212-983-1702 ext. 209 212-983-1702 ext. 207